TNF and autoimmune disease: Recently, several studies have suggested that targeted inhibition of TNF-α (by monoclonal antibodies (anti-TNF-α), such as certolizumab pegol (CZP) and infliximab (IFX), is a standard therapy for autoimmune diseases [112].